Alternatives to Network Bio

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

A nonprofit research organization leveraging AI and biotechnology to understand and treat complex diseases.

AI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.

AI-native biotech company designing next-generation CAR T therapies for solid tumors.

Developing oral small molecule medicines for immunological and chronic diseases.

Advancing next-generation mRNA medicines.

Scalable, one-time curative in-vivo gene editing therapies.

Decoding the immune system to pioneer a paradigm shift in disease diagnosis and treatment.

AI-enabled technology for cell biology research and biopharma development.

Space BioTech startup developing an autonomous, high-throughput screening platform for drug discovery in microgravity.

Developing precision medicines for inflammatory and immune-mediated diseases using AI and patient sample analysis.

Engineering-driven DNA design platform to overcome biological barriers in genetic medicines.

Advancing biopsy specimen stewardship and expanding access to precision oncology.

Biotechnology company defining membrane protein spatial relationships to create novel therapeutics for cancer and autoimmune diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Developing an automated platform for liquid biopsy sample preparation.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

A vertically-integrated procurement platform for the life sciences industry.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.

Engineering scalable gene therapies for broader patient populations.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.

Developing novel therapies to reverse aging and extend lifespan.

A biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Unlocking industrial-scale RNA-seq for primary drug screening and toxicology.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

AI biologist platform accelerating preclinical drug development by integrating biological data for smarter decisions.

Leveraging the adaptive immune system to diagnose and treat disease.

A biotechnology company focused on oncology drug discovery.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Developing a new histotripsy therapeutic platform for cancer treatment.

Platform designed to cut cell and gene therapy production costs.

AI drug discovery startup that learns directly from patient biology to identify and design novel medicines, focusing on oncology and fibrosis.

AI-powered spatial biology platform for precision medicine and drug development.

AI-powered platform for profiling cancer biomarkers from digitized biopsy images.

Developing disease-responsive advanced therapies through programmable gene control technology.

Atomwise uses AI to accelerate the discovery of novel small molecule therapeutics with its AtomNet platform.

Developing breath-based diagnostics for lung diseases.

Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.

AI-powered blood test for early cancer detection and subtyping.

Clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment.

AI-powered platform for personalized cell therapy development and manufacturing.

Personalized medicine startup focused on accurate cancer treatment through advanced diagnostics and functional drug sensitivity testing.

Cassidy Bio is an AI-driven company accelerating gene editing therapeutic development with bespoke solutions for faster, smarter R&D decisions.

Develops human antibodies targeting functional epitopes for challenging therapeutic areas using AI-driven computational design.

AI-powered breast cancer detection and risk assessment solutions.

Leveraging proteomic pattern analysis to personalize cancer treatment and improve patient outcomes.

AI-powered epiproteomic analysis platform for mass spectrometry data.